Jarod Parrish

Jarod Parrish

Assistant Professor

College of Pharmacy & Health Sciences

PharmD University of Tennessee College of Pharmacy; BA (Exercise Physiology) University of Tennessee

Location: McWhorter Hall 331

615-460-8084
jarod.parrish@belmont.edu

Biography

Dr. Jarod Parrish, an honors graduate from the University of Tennessee College of Pharmacy, began his career as a Community Pharmacist at Target Pharmacy, where he swiftly advanced to the role of Pharmacy Manager and served as a preceptor for both introductory and advanced pharmacy practice experiences. His most recent role was as a Clinical Research Pharmacist at Vanderbilt University Medical Center, where he contributed to a National Institutes of Health (NIH) funded research grant focused on addressing health disparities among African American males.

As an Assistant Professor of Pharmacy Practice, Dr. Parrish specializes in Population Health and Hypertension. He co-instructs courses in Self Care Therapeutics for second-year pharmacy students and Health Assessment for first-year students. His Pharmacy Practice site at Vanderbilt Health Affiliated Network (VHAN) involves collaboration with the Population Health/Medication Management team, providing chronic care management services and contributing to the development of clinical pharmacy programs and strategies. Dr. Parrish's research interests center on health communication in chronic conditions.

I am glad to be at Belmont University because the school provides an innovative teaching environment, as well as displaying a family-oriented academic culture that allows students and faculty to thrive in all current and future endeavors.

Hypertension
Quality Improvement
DEIA
SDOH
Health care communication
AI in healthcare and education
Pharmacogenomics

AACP

Tennessee Pharmacy Association

 

1. Parrish J, Blyler C, Okafor H, Chang C, Nair D, etc. Results of The Nashville Barber-pharmacist Hypertension Management Pilot Study. AHA Hypertension. 2021;78:A53

1) Enhancing Patient Outcomes
2)Entresto (Sacubitril/Valsartan): First-In-Class Angiotensin Receptor Neprilysin Inhibitor FDA approved for Patients with Heart Failure
3) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
4) Telmisartan and cardioprotection
5) A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops
6) Health in the African American Community: Becoming Trustworthy